Author:
Azzariti Amalia,Porcelli Letizia,Simone Grazia M.,Quatrale Anna E.,Colabufo Nicola A.,Berardi Francesco,Perrone Roberto,Zucchetti Massimo,D’Incalci Maurizio,Xu Jian Ming,Paradiso Angelo
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference37 articles.
1. Zhong H, Bowen JP (2007) Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 7:1379–1393
2. Press MF, Lenz HJ (2007) EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67:2045–2075
3. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12:7242–7251
4. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A (2006) The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766:120–139
5. Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A (2004) Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells. Br J Cancer 91:1964–1969
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献